NF-κB Inhibition in Amyotrophic Lateral Sclerosis

Phase 2 Unknown 75 enrolled Sunnybrook Health Sciences Centre

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start: 2021-10-19
Primary completion: 2022-07
Completion: 2022-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ashwagandha	Traditional medicine (herbal / TCM)	272 mg	Oral
Subject	Ashwagandha	Traditional medicine (herbal / TCM)	544 mg	Oral

NF-κB Inhibition in Amyotrophic Lateral Sclerosis

Summary

Timeline

Drugs

Indications